Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CoTIL 01

Next Previous
Drug Profile

CoTIL 01

Alternative Names: Autologous gene modified tumour infiltrating lymphocytes; CoTIL-01; CoTIL-01 - Immetacyte; Gene modified Tumour Infiltrating Lymphocytes; Tumour infiltrating lymphocyte therapy - Cellular Therapeutics

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellular Therapeutics
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Ovarian cancer

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for preclinical development in Ovarian-cancer in United Kingdom (Parenteral, Infusion)
  • 23 Dec 2020 Cellular Therapeutics withdrew a phase I/IIa OVSTAR trial in Ovarian cancer in United Kingdom (Parenteral) due to sponsor's decision (NCT04389229)
  • 01 Dec 2020 Preclinical trials in Ovarian cancer in United Kingdom (Parenteral) before December 2020 (NCT04389229)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top